• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
3-Bromo-4-fluorobenzaldehyde
5-Methyl-1,3,4-oxadiazol2(3H)-one
4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride
4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine
3-Pyridinecarboxaldehyde
Ethyl 3 Fluorobenzoate

Hikma, GSK stop talks over potential buyout deal of Egypt, Tunisia assets

expresspharmaMarch 12, 2021

Tag: Hikma , GSK , Egypt , Tunisia

Hikma Pharmaceuticals and GlaxoSmithKline have ended talks over a potential buyout deal for the latter’s pharma, consumer commercialisation and manufacturing business in Egypt and its drugs business in Tunisia, the companies said.

Hikma, which supplies generic drugs including anaesthetics, pain medications, sedatives, neuromuscular blocking agents and anti-infectives, had said in January it was planning to buy those assets.

Previous:Vir, GSK to seek EUA for COVID-19 antibody therapy

Next:Enveric Biosciences acquires licence for Diverse Biotech’s novel molecules

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

Hikma, GSK stop talks over potential buyout deal of Egypt, Tunisia assets | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

You may like
More>>

GSK1265744 (sodium salt)

GSK1265744 (sodium salt)
Cabotegravir (GSK744, GSK1265744)

Cabotegravir (GSK744, GSK1265744)
Dabrafenib(GSK2118436）

Dabrafenib(GSK2118436）
Dolutegravir (GSK1349572)

Dolutegravir (GSK1349572)
GSK 1349572

GSK 1349572
Trametinib(GSK1120212)

Trametinib(GSK1120212)
Dolutegravir GSK 1349572

Dolutegravir GSK 1349572
GSK2636771

GSK2636771
PHENOXYMETHYL PENICILLIN POTASSIUM

PHENOXYMETHYL PENICILLIN POTASSIUM
LINCOMYCIN HCL

LINCOMYCIN HCL

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service